Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

Journal of Medical Virology

Volumn 92, Issue 9, 2020, Pages 1533-1541

  Qu, Rong ^a   Ling, Yun ^a   Zhang, Yi hui zhi ^b   Wei, Li ya ^b   Chen, Xiao ^b   Li, Xu mian ^b   Liu, Xuan yong ^b   Liu, Han mian ^a   Guo, Zhi ^b,c   Ren, Hua ^b   Wang, Qiang ^c  

^a HUIZHOU MUNICIPAL CENTRAL HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

coronavirus disease; cytokine storm; platelet value; platelet to lymphocyte ratio; risk factor

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORONAVIRUS DISEASE 2019; CORRELATION ANALYSIS; CYTOKINE STORM; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; MALE; PLATELET LYMPHOCYTE RATIO; PNEUMONIA; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; BLOOD; CYTOKINE RELEASE SYNDROME; DIAGNOSIS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MIDDLE AGED; MORTALITY; PLATELET COUNT; SEVERITY OF ILLNESS INDEX; VIROLOGY; X-RAY COMPUTED TOMOGRAPHY;

BIOLOGICAL MARKER;

ADULT; AGED; BIOMARKERS; COVID-19; CYTOKINE RELEASE SYNDROME; FEMALE; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; SARS-COV-2; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85082322413     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.25767     Document Type: Article

References (32)

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-773.
2. Zhang MQ, Wang XH, Chen YL, et al. Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E013.
3. Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 novel coronavirus. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E002.
4. Mattiuzzi C, Lippi G. Which lessons shall we learn from the 2019 novel coronavirus outbreak? Ann Transl Med. 2020;8(3):48.
5. Han W, Quan B, Guo Y, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol. 2020;92:461-463. https://doi.org/10.1002/jmv.25711
6. Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications of virus origins and receptor binding. Lancet. 2020;395:565-574. https://doi.org/10.1016/S0140-6736(20)30251-8
7. Nguyen TM, Zhang Y, Pandolfi PP. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Res. 2020;30(3):189-190. https://doi.org/10.1038/s41422-020-0290-0
8. Tian X, Li C, Huang A, et al. Potentbinding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific humanmonoclonal antibody. Emerg Microbes Infect. 2020;9(1):382-385.
9. Yang M, Hon KL, Li K, Fok TF, Li CK. The effect of SARS coronavirus on blood system:its clinical findings and the pathophysiologichypothesis. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11(3):217-221.
10. Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 2015;26(4):286-292.
11. Güneş M, Büyükgöl H. Relationship between generalized epileptic seizure and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and neutrophil mediated inflammation. Int J Neurosci. 2020:1-6. https://doi.org/10.1080/00207454.2020.1722662
12. Chen RF, Chang JC, Yeh WT, et al. Role of vascular cell adhesion molecules and leukocyte apoptosis in the lymphopenia and thrombocytopenia of patients with severe acute respiratory syndrome (SARS). Microbes Infect. 2006;8(1):122-127.
13. Ji HL, Song W, Gao Z. SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms. Am J Physiol Lung Cell Mol Physiol. 2009;296(3):L372-L383.
14. Kumar PS, Chandrasekhar C, Srikanth L, Sarma PVGK. In vitro large scale production of megakaryocytes to functional platelets from human hematopoietic stem cells. Biochem Biophys Res Commun. 2018;505(1):168-175.
15. Behrens K, Alexander WS, Alexander WS. Cytokine control of megakaryopoiesis. Growth Factors. 2018;36(3-4):89-103.
16. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020:e201585. https://doi.org/10.1001/jama.2020.1585
17. Rousanusan TA, Aldoss IT, Cowley BD Jr, et al. Recurrent acute thrombocytopenia in the hospitalized patient: sepsis, DIC, HIT, or antibiotic-induced thrombocytopenia. Am J Hematol. 2010;85(1):71-74.
18. Eickmann M, Gravemann U, Handke W, et al. Inactivation of three emerging viruses severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus - in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. Vox Sang. 2020. https://doi.org/10.1111/vox.12888
19. Poon TCW, Pang RTK, Chan KCA, et al. Proteomic analysis reveals platelet factor 4 and beta-thromboglobulin as prognostic markers in severe acute respiratory syndrome. Electrophoresis. 2012;33(12):18941900.
20. Pilaczyńska-Cemel M, Gołda R, Dąbrowska A, Przybylski G. Analysis of the level of selected parameters of inflammation,circulating immune complexes,and related indicators (neutrophil/lymphocyte, platelet/lymphocyte, CRP/CIC) in patients with obstructive diseases. Cent Eur J Immunol. 2019;44(3):292-298.
21. Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J Virol. 2012;86(11):6055-6066.
22. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan,China[J]. Lancet. 2020;395(10223):497-506.
23. Ramana CV, DeBerge MP, Kumar A, Alia CS, Durbin JE, Enelow RI. Inflammatory impact of IFN-γ in CD8+T cellmediated lung injury is mediated by both Stat1-dependent and-independent pathways. Am J Physiol Lung Cell Mol Physiol. 2015;308(7):L650-L657.
24. Liu Y, Gayle AA, Wilder-Smith A, Rocklöv J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27:taaa021. https://doi.org/10.1093/jtm/taaa021
25. Peiris J, Hui KP, Yen HL. Host response to influenza virus: protection versus immunopathology. Curr Opin Immunol. 2010;22(4):475-481.
26. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection:a nationwide analysis in China. Lancet Oncol. 2020;21:335-337. https://doi.org/10.1016/S1470-2045(20)30096-6
27. Kudo K, Takasaki J, Manabe T, et al. Systemic corticosteroids and early administration of antiviral agents for pneumonia with acute wheezing due to influenza A(H1N1)pdm09 in Japan. PLoS One. 2012;7(2):e32280.
28. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001316
29. Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2019;4(1):23-35.
30. Sun ML, Yang JM, Sun YP. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E014. https://doi.org/10.3760/cma.j.issn.1001-0939.2020.0014
31. Malik YS, Sircar S, Bhat S, et al. Emerging novel Coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q. 2020;40:68-76. https://doi.org/10.1080/01652176.2020.1727993
32. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92:491-494. https://doi.org/10.1002/jmv.25709